With all the talk about new HIV prevention products such as the dapivirine vaginal ring or injectable cabotegravir for PrEP, what’s little understood is how to match proven products with programs, policies and the political will that's needed to get these products to the people who need them. PEPFAR Ambassador Dr. John Nkengasong shares his plan for meeting the moment. Also in this episode, seasoned advocates take on what's working and what's missing in programs today, and the expanding role of civil society in global strategies to end AIDS by 2030. 

In this episode, AVAC’s Jeanne Baron and co-host immunologist Katharine Kripke of AVENIR Health explore why developing a vaccine for HIV is different from other viruses.  Two vaccine researchers, Caltech’s Pamela Bjorkman and IAVI’s Vincent Kioi, lend their expertise. 

Learn how HIV has evolved like no other virus that exists today to escape detection by the immune system. Learn why the right target on HIV is so hard to reach and how scientists are tackling it all.

 Linda-Gail Bekker from South Africa’s Desmond Tutu Health Foundation and Lillian Mworeko from the International Community of Women Living with HIV East Africa (ICWEA) join host Jeanne Baron and AVAC’s Executive Director Mitchell Warren to discuss innovative models for scale-up and delivery. Taking the right steps now could mean HIV prevention options fulfill their life-saving, epidemic-ending potential. It will require working faster and more efficiently than ever before. We dive into what lessons the field has learned, what’s still off-track, and the steps advocates, policy-makers, drug makers and funders should each take right now to turn efficacious options into effective choices.

Endpoints are a crucial component in every clinical trial but they are not always well understood, and putting them in context is essential for effective advocacy.  This next installment of the Px Pulse series, Research Fundamentals, which explores key scientific concepts, lays out what endpoints are and why they matter. 

The latest episode of Px Pulse goes behind the scenes of the new HBO movie, The Legend of the Underground. The film documents the lives of AVACer Micheal Ighodaro and other LGBTQ Nigerians as they confront enormous risks to ‘live out loud’. 

The latest episode of Px Pulse takes a deep dive into PEPFAR, The President’s Emergency Plan for AIDS Relief. AVAC’s former Director of Strategy and Content, Emily Bass, has just published To End a Plague: America’s fight to end AIDS in Africa which documents its pioneering successes and its challenges. 

Findings from two trials on antibody-mediated prevention, the AMP Trials, have been generating discussion since the beginning of the year. The results are complex, and the implications for HIV prevention research are unfolding.

Early results from trials testing cabotegravir as a long-acting injectable PrEP show it was safe and highly effective against HIV. Listen to learn what must come next for CAB-LA to advance HIV prevention alongside oral PrEP and the Dapivirine Vaginal Ring?

After decades of research and advocacy, the ring is now one step closer to becoming available as a discreet, woman-initiated HIV prevention option. 

Whether it’s condoms, a flu shot, oral PrEP or the dapivirine vaginal ring, proven products fall short of 100 percent protection against disease, and there’s a lot to know about how and why an intervention may offer imperfect but still useful protection. This episode is part of a new series on Px Pulse, Research Fundamentals